Video

Other Frontline Immunotherapy-based Combinations in Advanced HCC

Author(s):

Michael A. Morse, MDNicole Rich, MD

Expert oncologists analyze immunotherapy-based combinations in the frontline setting for patients with hepatocellular carcinoma.

Related Videos
Piotr Rutkowski, MD
Yelena Y. Janjigian, MD
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Zhi Peng, MD
Josep Llovet, MD
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Ruihua Xu, MD, PhD, professor, medical oncology, Department of Medical Oncology, president, Sun Yat-sen University Cancer Center, chairman, Chinese Society of Clinical Oncology
Related Content
FDA
October 9th 2024

FDA Grants Orphan Drug Designation to Namodenoson for Pancreatic Cancer

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

The FDA’s ODAC votes against the risk:benefit profile of frontline PD-1 inhibitors in select tumor types, osimertinib gains approval for select NSCLC, and more this week from OncLive.
September 28th 2024

The OncFive: Top Oncology Articles for the Week 9/22

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Ruihua Xu, MD, PhD, of Sun Yat-sen University Cancer Center
September 25th 2024

Toripalimab Plus Chemo Wins European Approval for Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma

The FDA has granted fast track designation to EO-3021 for use in select patients with claudin 18.2–expressing gastric or GEJ cancer.
September 24th 2024

FDA Grants Fast Track Status to EO-3021 for CLDN18.2-Expressing Gastric or GEJ Cancer